Founded in 2001, TaiGen Biotechnology Co., Ltd. is a research-based and market-driven pharmaceutical company engaging in the development of novel therapeutics for infectious diseases. TaiGen has a wholly-owned Beijing subsidiary with proven capacities to conduct clinical trials and related registrations. TaiGen Biotechnology became a publicly listed company in Taipei Exchange (Ticker 4157.TWO) in January 2014.
TaiGen’s pipeline includes in-house discovered and developed new chemical entities: TG-1000, a novel antiviral for influenza, receives China and US IND authorization in May 2020 and Nov 2020 respectively. Taigexyn®, a novel antibiotic with capsule and intravenous infusion formulations, is one of the first NCEs developed by a Taiwanese company that received market approval and launched in mainland China and Taiwan. Taigexyn® is partnered in 36 countries worldwide. Licensed partners include Luminarie Canada for Canada, New Zealand and Australia; GPCR for South Korea; R-Pharm for the Russian Federation and the Commonwealth of Independent States; Productos Científicos for Latin America; and Holding Distribution for distribution in Taiwan.
Furaprevir, a HCV NS3/4A protease inhibitor, completed Phase 2 clinical trial in HCV genotype 1b patients in Taiwan. In 2016, TaiGen Biotechnology signed an agreement to form a new company with YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in mainland China for the joint development and commercialization of direct-acting antiviral agents (DAAs) for HCV treatment in the Greater China area. The phase III trial enrollment has been completed in December 2019.
|2001||TaiGen Taiwan Co. Ltd. established with paid-in capital of NT$10,000,000.|
|2004||TaiGen Biopharmaceuticals Beijing was established in 2004 with major focus on clinical development and regulatory affairs with China FDA.|
|2014||TaiGen Biopharmaceuticals Holdings Ltd Publicly listed in Taipei Exchange (TPEx) since January 2014.|
|2015||Received market approval of Nemonoxacin capsule from TFDA in January 2015.|
|2016||Taigexyn® ( Nemonoxacin)capsule received CFDA market approval in June 2016 and launched in mainland China by Zhejiang Medicine Co. on October 23, 2016.|
|2016||Signed an agreement to establish a New Company with HEC in China for the joint development and commercialization of direct-acting antiviral agents (DAAs) * for HCV treatment in the Greater China region.|
|2018||Taigexyn® intravenous and oral formulations successfully completed phase 3 clinical trial for community acquired pneumonia in Russia.|
|2019||TaiGen has completed enrollment for the phase III trial of Furaprevir and Yimitasvir combination Treatment in China.|
|2020||TaiGen receive TG-1000 clinical trial authorization from China NMPA|
|2020||Received market approval of Nemonoxacin intravenous infusion from TFDA in October 2020.|
|2020||TaiGen initiated phase II trial of TG-1000 under US and China IND|
|2021||Taigexyn® ( Nemonoxacin) intravenous infusion received NMPA market approval in June 2021|